-
Something wrong with this record ?
Real-time analysis of imatinib- and dasatinib-induced effects on chronic myelogenous leukemia cell interaction with fibronectin
A. Obr, P. Röselová, D. Grebeňová, K. Kuželová,
Language English Country United States
Document type Journal Article, Research Support, Non-U.S. Gov't
NLK
Directory of Open Access Journals
from 2006
Free Medical Journals
from 2006
Public Library of Science (PLoS)
from 2006
PubMed Central
from 2006
Europe PubMed Central
from 2006
ProQuest Central
from 2006-12-01
Open Access Digital Library
from 2006-10-01
Open Access Digital Library
from 2006-01-01
Open Access Digital Library
from 2006-01-01
Medline Complete (EBSCOhost)
from 2008-01-01
Nursing & Allied Health Database (ProQuest)
from 2006-12-01
Health & Medicine (ProQuest)
from 2006-12-01
Public Health Database (ProQuest)
from 2006-12-01
ROAD: Directory of Open Access Scholarly Resources
from 2006
- MeSH
- Cell Adhesion drug effects MeSH
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive pathology MeSH
- Dasatinib pharmacology MeSH
- Fibronectins metabolism MeSH
- Phosphorylation drug effects MeSH
- Imatinib Mesylate pharmacology MeSH
- Kinetics MeSH
- Humans MeSH
- Cell Line, Tumor MeSH
- Antineoplastic Agents pharmacology MeSH
- src-Family Kinases metabolism MeSH
- Protein Transport drug effects MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Attachment of stem leukemic cells to the bone marrow extracellular matrix increases their resistance to chemotherapy and contributes to the disease persistence. In chronic myelogenous leukemia (CML), the activity of the fusion BCR-ABL kinase affects adhesion signaling. Using real-time monitoring of microimpedance, we studied in detail the kinetics of interaction of human CML cells (JURL-MK1, MOLM-7) and of control BCR-ABL-negative leukemia cells (HEL, JURKAT) with fibronectin-coated surface. The effect of two clinically used kinase inhibitors, imatinib (a relatively specific c-ABL inhibitor) and dasatinib (dual ABL/SRC family kinase inhibitor), on cell binding to fibronectin is described. Both imatinib and low-dose (several nM) dasatinib reinforced CML cell interaction with fibronectin while no significant change was induced in BCR-ABL-negative cells. On the other hand, clinically relevant doses of dasatinib (100 nM) had almost no effect in CML cells. The efficiency of the inhibitors in blocking the activity of BCR-ABL and SRC-family kinases was assessed from the extent of phosphorylation at autophosphorylation sites. In both CML cell lines, SRC kinases were found to be transactivated by BCR-ABL. In the intracellular context, EC50 for BCR-ABL inhibition was in subnanomolar range for dasatinib and in submicromolar one for imatinib. EC50 for direct inhibition of LYN kinase was found to be about 20 nM for dasatinib and more than 10 µM for imatinib. Cells pretreated with 100 nM dasatinib were still able to bind to fibronectin and SRC kinases are thus not necessary for the formation of cell-matrix contacts. However, a minimal activity of SRC kinases might be required to mediate the increase in cell adhesivity induced by BCR-ABL inhibition. Indeed, active (autophosphorylated) LYN was found to localize in cell adhesive structures which were visualized using interference reflection microscopy.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16000635
- 003
- CZ-PrNML
- 005
- 20200120154727.0
- 007
- ta
- 008
- 160108s2014 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1371/journal.pone.0107367 $2 doi
- 035 __
- $a (PubMed)25198091
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Obr, Adam $u Department of Cellular Biochemistry, Institute of Hematology and Blood Transfusion, Prague, Czech Republic; Department of Cell Biology, Faculty of Science, Charles University in Prague, Prague, Czech Republic.
- 245 10
- $a Real-time analysis of imatinib- and dasatinib-induced effects on chronic myelogenous leukemia cell interaction with fibronectin / $c A. Obr, P. Röselová, D. Grebeňová, K. Kuželová,
- 520 9_
- $a Attachment of stem leukemic cells to the bone marrow extracellular matrix increases their resistance to chemotherapy and contributes to the disease persistence. In chronic myelogenous leukemia (CML), the activity of the fusion BCR-ABL kinase affects adhesion signaling. Using real-time monitoring of microimpedance, we studied in detail the kinetics of interaction of human CML cells (JURL-MK1, MOLM-7) and of control BCR-ABL-negative leukemia cells (HEL, JURKAT) with fibronectin-coated surface. The effect of two clinically used kinase inhibitors, imatinib (a relatively specific c-ABL inhibitor) and dasatinib (dual ABL/SRC family kinase inhibitor), on cell binding to fibronectin is described. Both imatinib and low-dose (several nM) dasatinib reinforced CML cell interaction with fibronectin while no significant change was induced in BCR-ABL-negative cells. On the other hand, clinically relevant doses of dasatinib (100 nM) had almost no effect in CML cells. The efficiency of the inhibitors in blocking the activity of BCR-ABL and SRC-family kinases was assessed from the extent of phosphorylation at autophosphorylation sites. In both CML cell lines, SRC kinases were found to be transactivated by BCR-ABL. In the intracellular context, EC50 for BCR-ABL inhibition was in subnanomolar range for dasatinib and in submicromolar one for imatinib. EC50 for direct inhibition of LYN kinase was found to be about 20 nM for dasatinib and more than 10 µM for imatinib. Cells pretreated with 100 nM dasatinib were still able to bind to fibronectin and SRC kinases are thus not necessary for the formation of cell-matrix contacts. However, a minimal activity of SRC kinases might be required to mediate the increase in cell adhesivity induced by BCR-ABL inhibition. Indeed, active (autophosphorylated) LYN was found to localize in cell adhesive structures which were visualized using interference reflection microscopy.
- 650 _2
- $a protinádorové látky $x farmakologie $7 D000970
- 650 _2
- $a buněčná adheze $x účinky léků $7 D002448
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a dasatinib $x farmakologie $7 D000069439
- 650 _2
- $a fibronektiny $x metabolismus $7 D005353
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imatinib mesylát $x farmakologie $7 D000068877
- 650 _2
- $a kinetika $7 D007700
- 650 _2
- $a chronická myeloidní leukemie $x patologie $7 D015464
- 650 _2
- $a fosforylace $x účinky léků $7 D010766
- 650 _2
- $a transport proteinů $x účinky léků $7 D021381
- 650 _2
- $a skupina kinas odvozených od src-genu $x metabolismus $7 D019061
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Röselová, Pavla $u Department of Cellular Biochemistry, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
- 700 1_
- $a Grebeňová, Dana $u Department of Cellular Biochemistry, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
- 700 1_
- $a Kuželová, Kateřina $u Department of Cellular Biochemistry, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
- 773 0_
- $w MED00180950 $t PloS one $x 1932-6203 $g Roč. 9, č. 9 (2014), s. e107367
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/25198091 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20160108 $b ABA008
- 991 __
- $a 20200120155103 $b ABA008
- 999 __
- $a ok $b bmc $g 1102916 $s 924841
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2014 $b 9 $c 9 $d e107367 $e 20140908 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
- LZP __
- $a Pubmed-20160108